Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-TNF discontinuation in inflammatory bowel disease
2015-001410-10Phase 4Completed
- Sponsor
- Fundación de Investigación Biomédica del Hospital Universitario de La Princesa
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of infliximab and adalimumab in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD) (2 arms), sponsored by Fundación de Investigación Biomédica del Hospital Universitario de La Princesa. Primary endpoint: Sustained clinical remission at 1 year. Started May 2016; status: completed.
02
Drugs
infliximabadalimumab
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2015-001410-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001410-10.